Springer Nature
Browse
10194_2019_1044_MOESM1_ESM.docx (39.02 kB)

Additional file 1: of Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

Download (39.02 kB)
journal contribution
posted on 2019-08-30, 04:38 authored by Robert Shapiro, Helen Hochstetler, Ellen Dennehy, Rashna Khanna, Erin Doty, Paul Berg, Amaal Starling
Supplemental materials. Table S1. Summary of events excluded from likely adverse events and the associated Standardized MedDRA Queries/Preferred Terms. Table S2. Summary and analysis of potential cardiovascular adverse events within Standardized MedDRA Queries/Preferred Terms. Table S3. Summary and analysis of likely cardiovascular adverse events within Standardized MedDRA Queries/Preferred Terms. Table S4. Summary of likely cardiovascular adverse events within Standardized MedDRA Queries/Preferred Terms in patients with and without aura. Table S5. Summary of likely cardiovascular treatment-emergent adverse events within Standardized MedDRA Queries/Preferred Terms in patients with and without aura. (DOCX 39 kb)

History